311.2 𩺠åèç
311.2.1 é«é »èé»
311.2.1.1 IPF
- UIP pattern: subpleural + basal + honeycombing + reticular
- Median survival 3-5 yr untreated
- Antifibrotic: pirfenidone (CAPACITY, ASCEND), nintedanib (INPULSIS)
- INBUILD: nintedanib for PPF any cause
- Acute exacerbation: 30-day mortality > 50%; high-dose steroids debated
311.2.1.2 CTD-ILD vs IPF
- CTD: younger, female, NSIP > UIP, immunosuppressive
- IPF: older, male, UIP, antifibrotic
311.2.1.5 PLCH
- Almost exclusively smokers
- Bizarre cysts + upper lobe + nodules
- Smoking cessation
- BRAF inhibitor for severe BRAF-mutated
311.2.2 ææ··æ·æ¯èŒ
| Disease | HRCT | Key Treatment |
|---|---|---|
| IPF | UIP (subpleural basal honeycomb) | Pirfenidone/nintedanib |
| NSIP | Bilateral GG + reticular | IS (MMF + steroids) |
| COP | Migratory consolidation | Steroids dramatic |
| AIP | Diffuse GG + consolidation | Supportive + steroids |
| PLCH | Upper lobe nodules + cysts | Smoking cessation |
| LAM | Diffuse thin-walled cysts | Sirolimus |
| PAP | âCrazy pavingâ | Whole lung lavage |
| Sarcoid | Hilar LAD ± parenchymal | Steroids ± IS |
311.2.3 Special Topics
311.2.3.1 GAP Score for IPF
- Gender, Age, Physiology (FVC, DLCO)
- Stage I, II, III
- Prognosis prediction
- Useful for transplant decisions